NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 15 hours 2 min ago

The Health of Sexual and Gender Minority (SGM) Populations (R21 Clinical Trial Optional)

Mon, 11/06/2017 - 09:54
Funding Opportunity PA-18-040 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.
Categories: NIH-Funding

The Health of Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)

Mon, 11/06/2017 - 09:52
Funding Opportunity PA-18-037 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.
Categories: NIH-Funding

Research on Informal and Formal Caregiving for Alzheimer's Disease (R01 Clinical Trial Optional)

Mon, 11/06/2017 - 09:50
Funding Opportunity PAR-18-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for basic and translational research on caregiving for individuals with Alzheimers disease (AD), at the individual, family, community, and population level. The scope of this funding opportunity includes support for applications that propose the following: interventions to reduce caregiver burden and improve patient outcomes across various settings; population- and community-based research on the scope and impact of AD caregiving; improved characterization of informal and formal caregiving and the burden of caregiving across the full spectrum of the disease, including differences amongsocioeconomic, racial/ethnic and geographic sub-populations; and research addressing the unique challenges related to the provision of advanced AD care, including disparities in access to care.
Categories: NIH-Funding

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)

Mon, 11/06/2017 - 09:48
Funding Opportunity PAR-18-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.
Categories: NIH-Funding

Systems Biology Approaches using Non-Mammalian Laboratory Animals to Uncover Causes of Neurodegeneration that Might Underlie Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

Mon, 11/06/2017 - 02:09
Funding Opportunity RFA-AG-18-021 from the NIH Guide for Grants and Contracts. The National Institute on Aging is seeking applications on systems biology approaches using non-mammalian laboratory animal models to increase our understanding of the basic biology underpinning neurodegeneration. It is expected that research supported under this FOA will provide new insights into molecular networks that might be involved in causing, amplifying or protecting against neurodegeneration, and that, in turn, might ultimately contribute to Alzheimer's disease or related dementias. Importantly, a major goal of this FOA is to use interaction and regulatory networks produced and analyzed using systems biology to gain these new insights. Because this FOA is directed toward discovery, currently employed genetically modified laboratory animals used to study AD are not required, although they may be used. Because this FOA requires systems biology approaches, data used to build interaction or regulatory networks may also come from humans or other mammals in which AD, related dementias, or aging-related cognitive decline have been observed. This FOA will only support studies using non-mammalian laboratory animal models; studies involving humans or experiments with mammals will not be allowed under this FOA.
Categories: NIH-Funding

Statement on Article Publication Resulting from NIH Funded Research

Fri, 11/03/2017 - 12:42
Notice NOT-OD-18-011 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Functional Wellness in HIV: Maximizing the Treatment Cascade (R21 Clinical Trial Optional)

Fri, 11/03/2017 - 12:08
Funding Opportunity PA-18-154 from the NIH Guide for Grants and Contracts. The National Institute of Nursing Research (NINR) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV.
Categories: NIH-Funding

Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)

Fri, 11/03/2017 - 12:06
Funding Opportunity PA-18-153 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years.
Categories: NIH-Funding

Functional Wellness in HIV: Maximizing the Treatment Cascade (R01 Clinical Trial Optional)

Fri, 11/03/2017 - 12:03
Funding Opportunity PA-18-136 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV.
Categories: NIH-Funding

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)

Fri, 11/03/2017 - 12:01
Funding Opportunity PA-18-134 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years.
Categories: NIH-Funding

Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)

Fri, 11/03/2017 - 11:59
Funding Opportunity PA-18-260 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings. The overall goal is to support changes to prevent or reduce exposure to harmful environmental exposures and improve the health of a community.
Categories: NIH-Funding

Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R03 Clinical Trial Optional)

Fri, 11/03/2017 - 11:57
Funding Opportunity PA-18-080 from the NIH Guide for Grants and Contracts. Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
Categories: NIH-Funding

Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R21 Clinical Trial Optional)

Fri, 11/03/2017 - 11:55
Funding Opportunity PA-18-079 from the NIH Guide for Grants and Contracts. Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
Categories: NIH-Funding

Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)

Fri, 11/03/2017 - 11:53
Funding Opportunity PA-18-078 from the NIH Guide for Grants and Contracts. Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.
Categories: NIH-Funding

Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01 Clinical Trial Optional)

Fri, 11/03/2017 - 11:51
Funding Opportunity PA-18-061 from the NIH Guide for Grants and Contracts. Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
Categories: NIH-Funding

Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional)

Fri, 11/03/2017 - 11:47
Funding Opportunity PA-18-060 from the NIH Guide for Grants and Contracts. Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.
Categories: NIH-Funding

Characterization of the Adolescent Reproductive Transition (R03 Clinical Trial Optional)

Fri, 11/03/2017 - 11:44
Funding Opportunity PA-18-046 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of puberty and the trajectory of sexual development. New technologies and approaches are needed to fill knowledge gaps and advance understanding of normative sexual development in both males and females. It is anticipated that the findings of studies supported by this FOA will advance knowledge of puberty and the establishment of reproductive competence
Categories: NIH-Funding

Characterization of the Adolescent Reproductive Transition (R21 Clinical Trial Optional)

Fri, 11/03/2017 - 11:41
Funding Opportunity PA-18-045 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of puberty and the trajectory of sexual development. New technologies and approaches are needed to fill knowledge gaps and advance understanding of normative sexual development in both males and females. It is anticipated that the findings of studies supported by this FOA will advance knowledge of puberty and the establishment of reproductive competence.
Categories: NIH-Funding

Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R03 Clinical Trial Optional)

Fri, 11/03/2017 - 11:37
Funding Opportunity PA-18-044 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to (1) promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations; and (2) develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments.
Categories: NIH-Funding